Trevi Therapeutics (TRVI) Tops Q3 EPS by 1c

Trevi Therapeutics (NASDAQ: TRVI) reported Q3 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Medtronic completes $550 million Scientia Vascular acquisition
• BIG3 Basketball to go public via Graf Global merger at $290 million